Summary
The influence of a 4-week treatment with the substituted benzimidazole omeprazole (20 mg daily) or placebo on gastric endocrine function was tested in healthy male volunteers. Compared with placebo-treated subjects basal serum gastrin levels were slightly but significantly increased after treatment with omeprazole from 10 to 22 pg/ml (medians;P<0.05) but returned to pretreatment values after 2 weeks recovery (9 pg/ml). Antral gastrin tissue concentration increased and was still elevated after recovery; however, antral gastrin concentrations also increased in placebo controls, and increments immediately after cessation of omeprazole treatment (2.58 µg/g; median) were not significantly over control values (1.92 µg/g;P>0.1). Postprandial gastrin release, basal and food-stimulated insulin release, antral somatostatin concentration, and volume densities of antral G and D cells were unaffected. It is concluded that, due to incomplete inhibition of gastric acid secretion at the omeprazole dose studied, only slight effects on the endocrine stomach are to be expected after 4 weeks of administration of omeprazole.
Similar content being viewed by others
Abbreviations
- SLI:
-
Somatostatin-like immunoreactivity
References
Allen JM, Bishop AE, Daly MJ, Larsson H, Carlsson E, Polak JM, Bloom SR (1986) Effect of inhibition of acid secretion on the regulatory peptides in the rat stomach. Gastroenterology 90:970–977
Allen JM, Adrian TE, Webster J, Howe A, Bloom SR (1984) Effect of single dose of omeprazole on the gastrointestinal peptide response to food. Hepatogastroenterology 31:44–46
Arnold R, von Hülst M, Neuhof C, Schwarting H, Becker HD, Creutzfeldt W (1982) Antral gastrin producing G-cells and somatostatin-producing D-cells in different states of gastric acid secretion. Gut 23:285–291
Cederberg C, Ekenved G, Lind T, Olbe L (1985) Acid inhibitory characteristics of omeprazole in man. Scand J Gastroent 20 [Suppl 108]:105–112
Cooperative study (1984) Omeprazole in duodenal ulceration: acid inhibition, symptom relief, endoscopic healing, and recurrance. Br Med J 289:525–528
Creutzfeldt W, Arnold R, Creutzfeldt C, Feurle G, Ketterer H (1971) Gastrin and G-cells in the antral mucosa of patients with pernicious anaemia, acromegaly and hyperparathyroidism and in a Zollinger-Ellison tumour of the pancreas. Eur J Clin Invest 1:461–479
Creutzfeldt W, Arnold R, Creutzfeldt C, Track NS (1976) Mucosal gastrin concentration, molecular forms of gastrin, number and ultrastructure of G-cells in patients with duodenal ulcer. Gut 17:745–754
Dammann HG, Müller P, Seitz HK, Simon B (1983) Säuresekretionsverhalten unter einer mehrtägigen Omeprazol-Gabe. Schweiz Med Wochenschr 113:895–898
Ekman L, Hansson E, Havu N, Carlsson E, Lundberg C (1985) Toxicological studies on omeprazole. Scand J Gastroent 20 [Suppl 108]:53–69
Fellenius E, Berglind T, Sachs G, Olbe L, Elander B, Sjöstrand SE, Wallmark B (1981) Substituted benzimidazoles inhibit gastric acid secretion. Nature (Lond) 290:159–161
Hirschowitz BI, Danilewitz M, Molina E (1982) Inhibition of basal acid, chloride, and pepsin secretion in duodenal ulcer by graded doses of ranitidine and atropine with studies of pharmacokinetics of ranitidine. Gastroenterology 82:1314–1326
Howden CW, Forrest JAH, Reid JL (1984) Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man. Gut 25:707–710
Konturek SJ, Kwiecien N, Obtulowicz W, Kopp B, Oleksy J (1984) Action of omeprazole (a benzimidazole derivate) on secretory responses to sham feeding and pentagastrin and upon serum gastrin and pancreatic polypeptide in duodenal ulcer patients. Gut 25:14–18
Lamers CBHW, Lind T, Moberg S, Jansen JBMJ, Olbe L (1984) Omeprazole in Zollinger-Ellison syndrome. N Engl J Med 310:758–761
Larsson H, Carlsson E, Mattison H, Lundell L, Sundler F, Sundell G, Wallmark B, Wantabe T, Hakanson R (1986) Plasma gastrin and gastric enterochromaffin-like cell activation and proliferation. Gastroenterology 90:391–399
Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L (1983) Effect of omeprazole — a gastric proton pump inhibitor — on pentagastrin stimulated acid secretion in man. Gut 24:270–276
Londong W, Londong V, Cederberg C, Steffen H (1983) Dose-response study of omeprazole on meal-stimulated gastric acid secretion and gastrin release. Gastroenterology 85:1373–1378
Mahachai V, Walker K, Thomson ABR (1985) Comparison of cimetidine and ranitidine on 24-h intragastric acidity and serum gastrin profile in patients with esophagitis. Dig Dis Sci 30:321–328
Mayer G, Arnold R, Feurle G, Fuchs K, Ketterer H, Track NS, Creutzfeldt W (1974) Influence of feeding and sham feeding upon serum gastrin and gastric acid secretion in control subjects and duodenal ulcer patients. Scand J Gastroent 9:703–710
McArthur KE, Collen MJ, Maton PN, Cherner JA, Howard JM, Ciarleglio CA, Cornelius MJ, Jensen RT, Gardner JD (1985) Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome. Gastroenterology 88:939–944
McGuigan JE, Trudeau WL (1970) Serum gastrin concentrations in pernicious anemia. N Engl J Med 282:358–361
McIntosh C, Arnold R, Bothe E, Becker H, Köbberling J, Creutzfeldt W (1978) Gastrointestinal somatostatin: extraction and radioimmunoassay in different species. Gut 19:655–663
McIntosh CHS, Pederson RA, Koop H, Brown JC (1981) Gastrin inhibitory polypeptide stimulated secretion of somatostatin-like immunoreactivity from the stomach: inhibition by acetylcholine and vagal stimulation. Can J Physiol Pharmacol 59:468–472
Mertz Nielsen A, Stenderup J, Wandall JH, Bonnevie O (1985) Reduction of gastric acid secretion by 10 mg and 30 mg Omeprazole once daily. Scand J Gastroent 20:1236–1238
Müller P, Simon B, Dammann HG, Feurle G, Lichtwald K, Schmidt-Gayk H (1984) Menschliche Säuresekretion unter täglich einmaliger Gabe von H2-Blockern. Schweiz Med Wochenschr 114:667–671
Öberg K, Lindström H (1983) Reduction of gastric hypersecretion in Zollinger-Ellison syndrome with omeprazole. Lancet I:66–67
Sachs L (1974) Angewandte Statistik. Springer, Berlin Heidelberg New York
Sharma BK, Walt RP, Pounder RE, Gomes M de FA, Wood EC, Logan LH (1984) Optimal dose of oral omeprazole for maximal 24-h decrease of intragastric acidity. Gut 25:957–964
Sternberger LA (1974) Immunocytochemistry. Prentice-Hall, Eaglewood Cliffs NJ
Stöckmann F, Fölsch UR, Bonatz G, Wülfrath M, Creutzfeldt W (1984) Influence of a substituted benzimidazole (omeprazole) on rat gastric endocrine cells. Dig Dis Sci 29 [Suppl]:A 82
Takemoto T, Okazaki Y, Okita K, Namiki M, Ishikawa M, Oshiba S, Kurokawa K (1981) Ranitidine: a pilot study in Japan. Scand J Gastroent 16 [Suppl 69]:125–128
Thompson JN, Barr JA, Collier N, Spencer J, Bush A, Cope L, Gribble RJN, Baron JH (1985) Basal, sham feeding and pentagastrin stimulated gastric acid, pepsin and electrolytes after omeprazole 20 mg and 40 mg daily. Gut 26:1018–1024
Walsh JH, Grossman MI (1975) Gastrin. N Engl J Med 292:1324–1334 and 1377–1384
Walt RP, Male PJ, Rawlings J, Hunt R, Milton-Thompson GJ, Misiewicz JJ (1981) Comparison of the effects of ranitidine, cimetidine and placebo on the 24-h intragastric acidity and nocturnal acid secretion in patients with duodenal ulcer. Gut 22:49–54
Walt RP, Gomes MdeFA, Wood EC, Logan LH, Pounder RE (1983) Effect of daily oral omeprazole on 24-h intragastric acidity. Br Med J 287:12–14
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Koop, H., Schwarting, H., Knorr-Marin, A. et al. Influence of chronic omeprazole treatment on gastric endocrine function. Klin Wochenschr 65, 169–173 (1987). https://doi.org/10.1007/BF01728228
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01728228